米格列醇与阿卡波糖治疗2型糖尿病的药物经济学研究  

Pharmacoeconomic Study of Miglitol and Acarbose in the Treatment of Type 2 Diabetes

作　　者：刘承统[1] Liu Chengtong(Affiliated Hospital of Youjiang Medical University for Nationalities,Baise,Guangxi 533000)

机构地区：[1]右江民族医学院附属医院,广西百色533000

出　　处：《中外健康》2024年第2期77-79,共3页

摘　　要：探究米格列醇与阿卡波糖治疗2型糖尿病(T2DM)的药物经济学效果。采用回顾性分析的方法,选取右江民族医学院附属医院2020年1月—2021年12月期间收治的50例T2DM患者设置为对照组,2022年1月—2023年12月期间收治的50例T2DM患者设置为试验组,两组均接受二甲双胍治疗,对照组在此基础上加用口服阿卡波糖,试验组加用口服米格列醇,均治疗12周,对比两组血糖水平、疗效变化,并计算用药成本,对其药物经济学进行分析。结果显示,治疗后,试验组血糖水平低于对照组(P<0.05);阿卡波糖、米格列醇的总成本分别为719.76元、655.92元;研究组方案疗效的成本-效果比低于对照组,且对照组方案相对于研究组的增量成本-效果比为10.64。研究发现米格列醇在控制血糖方面具有良好效果,且成本花费较低,是治疗T2DM更为经济有效的选择,可提高医疗资源利用效率,值得推广。To explore the pharmacoeconomic effect of miglitol and acarbose in the treatment of type 2 diabetes(T2DM).Using a retrospective analysis method,50 T2DM patients admitted to the Affiliated Hospital of Youjiang Medical University for Nationalities from January 2020 to December 2021 were selected as the control group,and 50 T2DM patients admitted from January 2022 to December 2023 were selected as the experimental group.Both groups received metformin treatment,and the control group received oral acarbose in addition to treatment.The experimental group received oral miglitol for 12 weeks.The changes in blood glucose levels and efficacy between the two groups were compared,and medication costs were calculated to analyze their pharmacoeconomics.The results showed that after treatment,the blood glucose level in the experimental group was lower than that in the control group(P<0.05);The total costs of acarbose and miglitol are 719.76 yuan and 655.92 yuan,respectively;The cost-effectiveness ratio of the study group's treatment plan is lower than that of the control group,and the incremental cost-effectiveness ratio of the control group's plan relative to the study group is 10.64.Research has found that Migliol has good effects in controlling blood sugar and is a cost-effective option for treating T2DM.It can improve the efficiency of medical resource utilization and is worth promoting.

关 键 词：米格列醇 阿卡波糖 2型糖尿病 药物经济学 

分 类 号：R587.1[医药卫生—内分泌]